The introduction of serum prostate specific antigen (PSA) screening led to a significant increase in the number of diagnosed cases [2] but failed to demonstrate a statistically significant prostate cancer mortality benefit [3]. This evidence concerns the gene KLK3 and prostate carcinoma.